Association of plasma ceramides and sphingomyelin with VLDL apoB-100 fractional catabolic rate before and after rosuvastatin treatment

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 6, 2015, Pages 2497-2501

  Ng, Theodore W K ^a,c   Ooi, Esther M M ^a   Watts, Gerald F ^a,b   Chan, Dick C ^a   Meikle, Peter J ^c   Barrett, P Hugh R ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; CERAMIDE; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; SPHINGOMYELIN; TRIACYLGLYCEROL; FLUOROBENZENE; HYPOCHOLESTEROLEMIC AGENT; PYRIMIDINE DERIVATIVE; SULFONAMIDE; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; EVENING DOSAGE; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CHEMISTRY; COMPLICATION; DRUG EFFECTS; KINETICS; LIPID METABOLISM; METABOLISM; OBESITY, ABDOMINAL;

ADULT; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN B-100; CERAMIDES; FLUOROBENZENES; HUMANS; KINETICS; LIPID METABOLISM; LIPOPROTEINS, VLDL; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; OBESITY, ABDOMINAL; PYRIMIDINES; SPHINGOMYELINS; SULFONAMIDES;

EID: 84930796690     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-4348     Document Type: Article

References (22)

1. Ford E, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among us adults: findings from the third national health and nutrition examination survey. JAMA. 2002;287:356-359.
2. Deedwania P, Barter P, Carmena R, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368:919-928.
3. Laaksonen R, Katajamaa M, Paiva H, et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PloS One. 2006;1:e97.
4. Bergheanu SC, Reijmers T, Zwinderman AH, et al. Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Curr Med Res Opin. 2008;24:2477-2487.
5. Tarasov K, Ekroos K, Suoniemi M, et al. Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency. J Clin Endocrinol Metab. 2014;99:E45-E52.
6. Ng TW, Ooi EMM, Watts GF, Chan DC, Meikle PJ, Barrett PHR. Dose-dependent effects of rosuvastatin on the plasma sphingolipidome and phospholipidome in the metabolic syndrome. J Clin Endocrinol Metab. 2014;99(11):E2335-E2340.
7. Chan DC, Watts GF, Barrett PH, Mori TA, Beilin LJ, Redgrave TG. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity. J Clin Endocrinol Metab. 2002;87:2283-2289.
8. Ooi EM, Barrett PH, Chan DC, Nestel PJ, Watts GF. Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome. Atherosclerosis. 2008;197:139-146.
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
10. Weir JM, Wong G, Barlow CK, et al. Plasma lipid profiling in a large population-based cohort. J Lipid Res. 2013;54:2898-2908.
11. Ooi EM, Watts GF, Nestel PJ, Sviridov D, Hoang A, Barrett PH. Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome. J Clin Endocrinol Metab. 2008;93:430-437.
12. Merrill AH Jr, Lingrell S, Wang E, Nikolova-Karakashian M, Vales TR, Vance DE. Sphingolipid biosynthesis de novo by rat hepatocytes in culture. Ceramide and sphingomyelin are associated with, but not required for, very low density lipoprotein secretion. J Biol Chem. 1995;270:13834-13841.
13. Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscl Thromb Vasc Biol. 2008;28:1225-1236.
14. Park TS, Panek RL, Rekhter MD, et al. Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice. Atherosclerosis. 2006;189:264-272.
15. Jeong T, Schissel SL, Tabas I, Pownall HJ, Tall AR, Jiang X. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J Clin Invest. 1998;101:905-912.
16. Schissel SL, Tweedie-Hardman J, Rapp JH, Graham G, Williams KJ, Tabas I. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest. 1996;98:1455-1464.
17. Arimoto I, Saito H, Kawashima Y, Miyajima K, Handa T. Effects of sphingomyelin and cholesterol on lipoprotein lipase-mediated lipolysis in lipid emulsions. J Lipid Res. 1998;39:143-151.
18. Bolin DJ, Jonas A. Sphingomyelin inhibits the lecithin-cholesterol acyltransferase reaction with reconstituted high density lipoproteins by decreasing enzyme binding. J Biol Chem. 1996;271:19152-19158.
19. Morita SY, Kawabe M, Sakurai A, et al. Ceramide in lipid particles enhances heparin sulfate proteoglycan and low density lipoprotein receptor-related protein-mediated uptake by macrophages. J Biol Chem. 2004;279:24355-24361.
20. Ooi EM, Watts GF, Chan DC, et al. Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome. Diabetes Care. 2008;31:1656-1661.
21. Holland WL, Miller RA, Wang ZV, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med. 2011;17:55-63.
22. Ng TW, Watts GF, Farvid MS, Chan DC, Barrett PH. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes. 2005;54:795-802.